Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 11 | 2026 | 91 | 1.950 |
Why?
|
| Laryngectomy | 5 | 2020 | 7 | 1.270 |
Why?
|
| Mouth Neoplasms | 2 | 2022 | 64 | 0.880 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 39 | 0.670 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2024 | 163 | 0.640 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2017 | 22 | 0.630 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2018 | 24 | 0.590 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2018 | 7 | 0.580 |
Why?
|
| Image-Guided Biopsy | 2 | 2018 | 20 | 0.570 |
Why?
|
| Larynx, Artificial | 1 | 2017 | 1 | 0.550 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 22 | 0.540 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 26 | 0.540 |
Why?
|
| Prosthesis Design | 1 | 2017 | 88 | 0.530 |
Why?
|
| Cutaneous Fistula | 3 | 2014 | 6 | 0.480 |
Why?
|
| Turbinates | 2 | 2006 | 2 | 0.470 |
Why?
|
| Parathyroidectomy | 3 | 2004 | 5 | 0.460 |
Why?
|
| Hyperparathyroidism | 3 | 2004 | 9 | 0.460 |
Why?
|
| Pharyngeal Diseases | 2 | 2014 | 5 | 0.460 |
Why?
|
| Fascia | 1 | 2014 | 5 | 0.440 |
Why?
|
| Pectoralis Muscles | 1 | 2014 | 13 | 0.430 |
Why?
|
| Skin Transplantation | 1 | 2014 | 15 | 0.430 |
Why?
|
| Surgical Flaps | 1 | 2014 | 24 | 0.430 |
Why?
|
| Middle Aged | 22 | 2026 | 7310 | 0.420 |
Why?
|
| Humans | 37 | 2026 | 28581 | 0.420 |
Why?
|
| Parathyroid Neoplasms | 2 | 2003 | 4 | 0.400 |
Why?
|
| Male | 26 | 2026 | 13771 | 0.390 |
Why?
|
| Catheter Ablation | 2 | 2006 | 223 | 0.390 |
Why?
|
| Hypercalcemia | 2 | 2021 | 13 | 0.380 |
Why?
|
| Female | 24 | 2026 | 15471 | 0.330 |
Why?
|
| Retrospective Studies | 12 | 2026 | 2612 | 0.330 |
Why?
|
| Tonsillar Neoplasms | 1 | 2010 | 1 | 0.320 |
Why?
|
| Neoplasm Staging | 5 | 2022 | 478 | 0.320 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 21 | 0.320 |
Why?
|
| Jaw Diseases | 1 | 2009 | 4 | 0.310 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2009 | 4 | 0.310 |
Why?
|
| Osteonecrosis | 1 | 2009 | 8 | 0.310 |
Why?
|
| Diphosphonates | 1 | 2009 | 15 | 0.300 |
Why?
|
| Osteoma | 1 | 2008 | 3 | 0.290 |
Why?
|
| Mandibular Neoplasms | 1 | 2008 | 5 | 0.290 |
Why?
|
| Mandibular Condyle | 1 | 2008 | 15 | 0.290 |
Why?
|
| Endoscopy | 1 | 2008 | 57 | 0.280 |
Why?
|
| Nasal Obstruction | 2 | 2006 | 6 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2017 | 1272 | 0.260 |
Why?
|
| Hyperostosis | 1 | 2006 | 1 | 0.250 |
Why?
|
| Aged | 13 | 2026 | 5525 | 0.250 |
Why?
|
| Epistaxis | 2 | 1996 | 7 | 0.240 |
Why?
|
| Treatment Outcome | 7 | 2026 | 2402 | 0.230 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 5 | 0.220 |
Why?
|
| Adult | 16 | 2024 | 7922 | 0.210 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 1026 | 0.210 |
Why?
|
| Parathyroid Glands | 1 | 2003 | 7 | 0.200 |
Why?
|
| Parathyroid Hormone | 4 | 2021 | 24 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 994 | 0.200 |
Why?
|
| Cysts | 1 | 2003 | 22 | 0.200 |
Why?
|
| Lymphatic Metastasis | 3 | 2018 | 126 | 0.190 |
Why?
|
| Adenoma | 1 | 2003 | 61 | 0.190 |
Why?
|
| Tobacco Use Cessation | 1 | 2022 | 30 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 74 | 0.180 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2021 | 2 | 0.180 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 13 | 0.180 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 524 | 0.170 |
Why?
|
| HIV Infections | 1 | 2022 | 161 | 0.170 |
Why?
|
| Patient Safety | 1 | 2020 | 38 | 0.160 |
Why?
|
| Time Factors | 3 | 2017 | 1600 | 0.160 |
Why?
|
| Postoperative Complications | 3 | 2017 | 631 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 147 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 90 | 0.150 |
Why?
|
| Tracheostomy | 1 | 1999 | 7 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.150 |
Why?
|
| Foreign Bodies | 1 | 1999 | 16 | 0.150 |
Why?
|
| Bronchi | 1 | 1999 | 38 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 478 | 0.150 |
Why?
|
| Malingering | 1 | 1998 | 10 | 0.150 |
Why?
|
| Posture | 1 | 1998 | 39 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 196 | 0.140 |
Why?
|
| Parotid Neoplasms | 1 | 1997 | 4 | 0.140 |
Why?
|
| Lipoma | 1 | 1997 | 11 | 0.140 |
Why?
|
| Voice Quality | 1 | 2017 | 3 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 2045 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 2 | 2014 | 8 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2014 | 35 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 302 | 0.130 |
Why?
|
| Eating | 1 | 2016 | 70 | 0.130 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 378 | 0.130 |
Why?
|
| Sickness Impact Profile | 1 | 2016 | 4 | 0.120 |
Why?
|
| Carcinoma | 2 | 2014 | 74 | 0.120 |
Why?
|
| Xerostomia | 1 | 2016 | 9 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 106 | 0.120 |
Why?
|
| Cerebral Arteries | 1 | 1996 | 33 | 0.120 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2016 | 25 | 0.120 |
Why?
|
| Oxymetazoline | 1 | 1995 | 2 | 0.120 |
Why?
|
| Intracranial Aneurysm | 1 | 1996 | 59 | 0.120 |
Why?
|
| Single-Blind Method | 2 | 2006 | 46 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 1996 | 93 | 0.110 |
Why?
|
| Palatal Neoplasms | 1 | 2014 | 2 | 0.110 |
Why?
|
| Palate, Hard | 1 | 2014 | 2 | 0.110 |
Why?
|
| Incidence | 2 | 2014 | 568 | 0.110 |
Why?
|
| Pain | 1 | 2016 | 258 | 0.110 |
Why?
|
| Fistula | 1 | 2014 | 17 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2008 | 414 | 0.100 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2014 | 72 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2006 | 461 | 0.100 |
Why?
|
| Enteral Nutrition | 2 | 2011 | 23 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 504 | 0.100 |
Why?
|
| Biopsy | 2 | 2014 | 207 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2003 | 77 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 61 | 0.090 |
Why?
|
| Gastroscopy | 1 | 2011 | 7 | 0.090 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2011 | 11 | 0.090 |
Why?
|
| Oklahoma | 1 | 2014 | 1038 | 0.080 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2010 | 5 | 0.080 |
Why?
|
| Round Window, Ear | 1 | 2010 | 10 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2010 | 37 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2010 | 63 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 67 | 0.080 |
Why?
|
| Hyaluronic Acid | 1 | 2010 | 96 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 472 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 29 | 0.070 |
Why?
|
| Cisplatin | 2 | 2008 | 183 | 0.070 |
Why?
|
| Tongue Neoplasms | 1 | 2008 | 6 | 0.070 |
Why?
|
| Survival Rate | 2 | 2026 | 431 | 0.070 |
Why?
|
| Open Bite | 1 | 2008 | 3 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2010 | 265 | 0.070 |
Why?
|
| Microsurgery | 1 | 2008 | 46 | 0.070 |
Why?
|
| Thyroid Nodule | 1 | 2008 | 8 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 27 | 0.070 |
Why?
|
| Risk Factors | 2 | 2010 | 2111 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 130 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 73 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 100 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 253 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2006 | 61 | 0.060 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2004 | 1 | 0.050 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2004 | 1 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2004 | 46 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2026 | 389 | 0.050 |
Why?
|
| Adolescent | 2 | 2024 | 3165 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 137 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 12 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 40 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2003 | 81 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 80 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2003 | 98 | 0.050 |
Why?
|
| Motivation | 1 | 2024 | 213 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2002 | 62 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 12 | 0.040 |
Why?
|
| Triamcinolone | 1 | 2000 | 2 | 0.040 |
Why?
|
| Granuloma, Giant Cell | 1 | 2000 | 3 | 0.040 |
Why?
|
| Maxillary Neoplasms | 1 | 2000 | 2 | 0.040 |
Why?
|
| Bupivacaine | 1 | 2000 | 4 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2002 | 117 | 0.040 |
Why?
|
| Biomarkers | 1 | 2024 | 770 | 0.040 |
Why?
|
| Calcium | 1 | 2021 | 243 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 732 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 13 | 0.040 |
Why?
|
| Patient Care | 1 | 2020 | 13 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2000 | 115 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 682 | 0.040 |
Why?
|
| Equipment Failure | 1 | 1999 | 31 | 0.040 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1999 | 31 | 0.040 |
Why?
|
| Vestibular Diseases | 1 | 1998 | 3 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2018 | 103 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 1999 | 58 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1998 | 58 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 2804 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 622 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1998 | 421 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 46 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 1996 | 38 | 0.030 |
Why?
|
| Osteotomy | 1 | 1996 | 24 | 0.030 |
Why?
|
| Mandible | 1 | 1996 | 43 | 0.030 |
Why?
|
| Cautery | 1 | 1995 | 1 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 1996 | 48 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1995 | 224 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 480 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 12 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2016 | 97 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 25 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 105 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2014 | 64 | 0.030 |
Why?
|
| Infant | 1 | 1997 | 1019 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 465 | 0.030 |
Why?
|
| Child | 1 | 2018 | 2271 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 409 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 28 | 0.020 |
Why?
|
| Perilymph | 1 | 2010 | 2 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 8 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 834 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2010 | 73 | 0.020 |
Why?
|
| Cachexia | 1 | 2011 | 53 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 101 | 0.020 |
Why?
|
| Oral Fistula | 1 | 2009 | 2 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 257 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 104 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2008 | 9 | 0.020 |
Why?
|
| Length of Stay | 1 | 2009 | 240 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 5 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 40 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2008 | 6 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 236 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 39 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2008 | 191 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 430 | 0.020 |
Why?
|
| Hydrochlorothiazide | 1 | 2006 | 2 | 0.020 |
Why?
|
| Atenolol | 1 | 2006 | 10 | 0.020 |
Why?
|
| Albuterol | 1 | 2006 | 4 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 458 | 0.020 |
Why?
|
| Creatinine | 1 | 2006 | 59 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2006 | 58 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 337 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 93 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 56 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2004 | 21 | 0.010 |
Why?
|
| Immunoassay | 1 | 2004 | 36 | 0.010 |
Why?
|
| Nurse's Role | 1 | 2002 | 18 | 0.010 |
Why?
|
| Morphine | 1 | 2002 | 29 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2002 | 46 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2002 | 50 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2000 | 6 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2002 | 164 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 10580 | 0.010 |
Why?
|